CL2012000551A1 - Molecula de union a antigeno (abm) porque dicho dominio de union a antigeno se une especificamente a antigeno carcinoembrionario humano (cea) unido a membrana; polipep que comprende dominio de union a antigeno que se une a cea; anticuerpo que se une a cea; composicion que comprende moleculas que se unen a cea. - Google Patents

Molecula de union a antigeno (abm) porque dicho dominio de union a antigeno se une especificamente a antigeno carcinoembrionario humano (cea) unido a membrana; polipep que comprende dominio de union a antigeno que se une a cea; anticuerpo que se une a cea; composicion que comprende moleculas que se unen a cea.

Info

Publication number
CL2012000551A1
CL2012000551A1 CL2012000551A CL2012000551A CL2012000551A1 CL 2012000551 A1 CL2012000551 A1 CL 2012000551A1 CL 2012000551 A CL2012000551 A CL 2012000551A CL 2012000551 A CL2012000551 A CL 2012000551A CL 2012000551 A1 CL2012000551 A1 CL 2012000551A1
Authority
CL
Chile
Prior art keywords
cea
antigen
binds
binding domain
polypep
Prior art date
Application number
CL2012000551A
Other languages
English (en)
Spanish (es)
Inventor
Ekkehard Moessner
Ralf Hosse
Pablo Umana
Thomas U Hofer
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000551(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CL2012000551A1 publication Critical patent/CL2012000551A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2012000551A 2009-08-31 2012-02-29 Molecula de union a antigeno (abm) porque dicho dominio de union a antigeno se une especificamente a antigeno carcinoembrionario humano (cea) unido a membrana; polipep que comprende dominio de union a antigeno que se une a cea; anticuerpo que se une a cea; composicion que comprende moleculas que se unen a cea. CL2012000551A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23850509P 2009-08-31 2009-08-31

Publications (1)

Publication Number Publication Date
CL2012000551A1 true CL2012000551A1 (es) 2012-10-12

Family

ID=42985489

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000551A CL2012000551A1 (es) 2009-08-31 2012-02-29 Molecula de union a antigeno (abm) porque dicho dominio de union a antigeno se une especificamente a antigeno carcinoembrionario humano (cea) unido a membrana; polipep que comprende dominio de union a antigeno que se une a cea; anticuerpo que se une a cea; composicion que comprende moleculas que se unen a cea.

Country Status (22)

Country Link
US (2) US9068008B2 (cg-RX-API-DMAC7.html)
EP (1) EP2473532B1 (cg-RX-API-DMAC7.html)
JP (1) JP5744872B2 (cg-RX-API-DMAC7.html)
KR (1) KR101528013B1 (cg-RX-API-DMAC7.html)
CN (1) CN102741293B (cg-RX-API-DMAC7.html)
AR (1) AR078111A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010288469A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012003983A2 (cg-RX-API-DMAC7.html)
CA (1) CA2770174A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012000551A1 (cg-RX-API-DMAC7.html)
CO (1) CO6491105A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120087A (cg-RX-API-DMAC7.html)
EC (1) ECSP12011698A (cg-RX-API-DMAC7.html)
IL (1) IL218038A0 (cg-RX-API-DMAC7.html)
MA (1) MA33536B1 (cg-RX-API-DMAC7.html)
MX (1) MX339608B (cg-RX-API-DMAC7.html)
PE (1) PE20121552A1 (cg-RX-API-DMAC7.html)
RU (1) RU2570554C2 (cg-RX-API-DMAC7.html)
SG (1) SG178567A1 (cg-RX-API-DMAC7.html)
TW (1) TW201121994A (cg-RX-API-DMAC7.html)
WO (1) WO2011023787A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200954B (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5992710A (ja) * 1982-11-16 1984-05-29 関西電力株式会社 直接水冷線路の立坑部の布設方法
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
HUE040326T2 (hu) 2011-02-10 2019-03-28 Roche Glycart Ag Mutáns interleukon-2 polipeptidek
US20120258073A1 (en) 2011-02-10 2012-10-11 Christian Gerdes Immunotherapy
RS56793B1 (sr) * 2011-03-02 2018-04-30 Roche Glycart Ag Cea antitela
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX356947B (es) 2011-08-23 2018-06-20 Roche Glycart Ag Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
CA2844538C (en) 2011-08-23 2020-09-22 Roche Glycart Ag Bispecific antigen binding molecules
EA030147B1 (ru) 2011-08-23 2018-06-29 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
WO2013054320A1 (en) * 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
GB201213858D0 (en) 2012-08-03 2012-09-19 Mab Design Ltd Method
AR092044A1 (es) 2012-08-07 2015-03-18 Roche Glycart Ag Inmunoterapia mejorada
US10087250B2 (en) 2012-10-08 2018-10-02 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
KR20180023035A (ko) 2013-02-26 2018-03-06 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
EP2961770A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
SG11201608772UA (en) 2014-04-27 2016-11-29 Ccam Biotherapeutics Ltd Humanized antibodies against ceacam1
PE20211533A1 (es) 2014-08-04 2021-08-16 Hoffmann La Roche Moleculas biespecificas de unon a antigeno activadoras de celulas t
LT3221357T (lt) 2014-11-20 2020-08-25 F. Hoffmann-La Roche Ag Bendros lengvosios grandinės ir naudojimo būdai
MX2017006571A (es) 2014-11-20 2017-09-29 Hoffmann La Roche Moleculas de union a antigeno biespecificas activadoras de celulas t.
HRP20201928T1 (hr) 2014-11-20 2021-02-05 F. Hoffmann - La Roche Ag Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
BR112018000835A2 (pt) 2015-10-02 2018-09-11 Hoffmann La Roche molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
ES2901794T3 (es) 2015-12-09 2022-03-23 Hoffmann La Roche Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
RS64266B1 (sr) 2016-03-22 2023-07-31 Hoffmann La Roche Bispecifični molekul koji aktivira t ćeliju koji se aktivira proteazom
CN107663240B (zh) 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
JP7022123B2 (ja) 2016-09-30 2022-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３に対する二重特異性抗体
CN118772288A (zh) 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
TWI849895B (zh) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
EP3992211A4 (en) * 2019-06-26 2023-01-04 Jiangsu Hengrui Medicine Co., Ltd. ANTI-CEA ANTIBODIES AND ITS USE
AU2020304813A1 (en) 2019-06-26 2022-01-06 F. Hoffmann-La Roche Ag Fusion of an antibody binding CEA and 4-1BBL
CN110862456B (zh) * 2019-09-23 2021-04-09 华道(上海)生物医药有限公司 一种抗癌胚抗原的抗体及其制备方法和用途
CN110713539B (zh) * 2019-09-23 2021-04-16 华道(上海)生物医药有限公司 一种抗癌胚抗原的抗体及其制备方法和用途
MX2022016069A (es) 2020-06-19 2023-02-02 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19.
AU2021329375A1 (en) 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
AU2021329371A1 (en) 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
JP2025504667A (ja) * 2022-01-27 2025-02-14 ヤンセン バイオテツク，インコーポレーテツド 増強されたタンパク質組成物
MX2024011519A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.
AU2024305352A1 (en) 2023-06-12 2025-12-04 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
WO2025257185A1 (en) * 2024-06-11 2025-12-18 Abcely Humanized anti-human-carcinoembryonic antigen antibody

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
CA2135059A1 (en) * 1992-05-07 1993-11-11 John L. Toner Complexing agents and targeting immunoreagents
GB9317423D0 (en) 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6815184B2 (en) 2000-07-31 2004-11-09 Biolex, Inc. Expression of biologically active polypeptide in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
NZ569490A (en) 2001-12-27 2008-11-28 Glycofi Inc Methods to engineer mammalian-type carbohydrate structures
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
AU2003219402B2 (en) 2002-03-19 2008-05-08 Stichting Dienst Landbouwkundig Onderzoek GnTIII (UDP-n-acethylglucosamine:beta-D mannoside beta (1,4)-N-acethylglucosaminy ltransferase III) expression in plants
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
CA2494310A1 (en) * 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
PT1539966E (pt) 2002-09-12 2010-09-14 Greenovation Biotech Gmbh Método de produção de proteínas
CA2549932C (en) 2002-12-20 2013-08-20 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
SG179292A1 (en) 2003-01-22 2012-04-27 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
AU2004239065B2 (en) * 2003-05-14 2008-05-15 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
RS56793B1 (sr) * 2011-03-02 2018-04-30 Roche Glycart Ag Cea antitela

Also Published As

Publication number Publication date
EP2473532A1 (en) 2012-07-11
KR20120060874A (ko) 2012-06-12
EP2473532B1 (en) 2017-06-21
SG178567A1 (en) 2012-04-27
CA2770174A1 (en) 2011-03-03
MX2012002461A (es) 2012-03-14
WO2011023787A1 (en) 2011-03-03
CN102741293B (zh) 2015-04-01
RU2012112340A (ru) 2013-10-10
TW201121994A (en) 2011-07-01
PE20121552A1 (es) 2012-11-26
JP5744872B2 (ja) 2015-07-08
US20160075795A1 (en) 2016-03-17
ECSP12011698A (es) 2012-03-30
HK1176951A1 (en) 2013-08-09
KR101528013B1 (ko) 2015-06-16
US20110104148A1 (en) 2011-05-05
CO6491105A2 (es) 2012-07-31
ZA201200954B (en) 2014-07-30
AU2010288469A1 (en) 2012-03-01
RU2570554C2 (ru) 2015-12-10
AR078111A1 (es) 2011-10-12
US9068008B2 (en) 2015-06-30
CR20120087A (es) 2012-03-22
MA33536B1 (fr) 2012-08-01
JP2013502913A (ja) 2013-01-31
CN102741293A (zh) 2012-10-17
BR112012003983A2 (pt) 2021-09-14
MX339608B (es) 2016-05-31
IL218038A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
CL2012000551A1 (es) Molecula de union a antigeno (abm) porque dicho dominio de union a antigeno se une especificamente a antigeno carcinoembrionario humano (cea) unido a membrana; polipep que comprende dominio de union a antigeno que se une a cea; anticuerpo que se une a cea; composicion que comprende moleculas que se unen a cea.
CY1116376T1 (el) Τρισθενη, διειδικα αντισωματα
CL2020000830A1 (es) Molécula de unión a cd3 que comprende un dominio variable de cadena ligera (vl) y un dominio variable de cadena pesada (vh) capaz de unir un epítope de cd3 humano y de mamíferos no humanos; composición farmacéutica que comprende dicha molécula y su uso. (divisional solicitud 201303329)
NI201200052A (es) Anticuerpos que se unen específicamente al receptor epha2
BRPI0812777A2 (pt) Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir
CU20190109A7 (es) Moléculas de anticuerpo que se unen a cd73
CL2011002380A1 (es) Anticuerpo multiespecifico que comprende un anticuerpo de longitud completa que se une especificamente a un primer antigeno y uno o mas fragmentos fab de cadena sencilla que se unen a uno o mas antigenos, acido nucleico que lo codifica; y composicion farmaceutica que lo comprende.
CL2013002203A1 (es) Molecula de union a antigeno (abm) que se une al antigeno carcinoembrionario humano (cea) unido a membrana; anticuerpo que se une a cea unido a membrana; polinucleotido que los codifica; vector; celula huesped; composicion que comprende al abm o al anticuerpo; y su uso para tratar un cancer que expresa niveles anormales de cea.
CR20110577A (es) Proteínas de unión a il-1
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
UA114707C2 (uk) БІСПЕЦИФІЧНА ЗВ'ЯЗУВАЛЬНА МОЛЕКУЛА, ЯКА ЗВ'ЯЗУЄТЬСЯ З VEGF I Ang2
DOP2009000236A (es) Anticuerpos de union a antigenos multiples
CY1118906T1 (el) Χαμηλης συγγενειας αντισωματα υποδοχεα αιματοεγκεφαλικου φραγμου και χρησεις αυτων
MX2016006572A (es) Construcciones de union a antigenos biespecificas dirigidas a her2.
AR080513A1 (es) Moleculas de union cd37 y sus inmunoconjugados
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
NZ608033A (en) Anti-ox40 antibodies and methods of using the same
MX364329B (es) Conjugados del anticuerpo pirrolobenzodiazepina.
CR20110559A (es) Anticuerpos específicos para cadherina-17
CR20130128A (es) Nuevas proteínas de unión a antígenos
CL2011002306A1 (es) Anticuerpo o un fragmento de union a antigeno del mismo que se une especificamente a la integrina heterodimero alfa4beta7; y composicion que lo comprende.
CA2808482C (en) Methods for the generation of multispecific and multivalent antibodies
CO7400860A2 (es) Anticuerpos anti-cd3, moléculas de unión a antígeno biespecíficas que se unen a cd3 y cd20, y usos de los mismos
MX356947B (es) Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
CL2012002428A1 (es) Anticurpos de dominio (dab) que se une a cd 28 e inhibe la union de cd28 a cd80 y/o cd86 y no reacciona en forma cruzada con ctla4; uso del anticuerpo para tratar una enfermedad inmune o relacionada con un injerto; composicion farmaceutica que lo comprende.